Ureaplasma urealyticum is a bacterium belonging to the genus Ureaplasma and the family Mycoplasmataceae in the order Mycoplasmatales. This family consists of the genera Mycoplasma and Ureaplasma. Its type strain is T960. There are two known biovars of this species; T960 and 27. These strains of bacteria are commonly found as commensals in the urogenital tracts of human beings. Unlike most bacteria, Ureaplasma urealyticum lacks a cell wall making it unique in physiology and medical treatment.

Classification

The six recognised Ureaplasma species have a GC content of 27 to 30 percent and a genome size ranging from 0.76 to 1.17 million base pairs, and cholesterol is required for growth. A defining characteristic of the genus is that they perform urea hydrolysis, which creates ammonia as a product. Some strains originally classified as U. urealyticum should be treated as a new species, U. parvum. Their sequences can be accessed through public records and databases. Most of the 16S rDNA sequence of the two strains constitute the exact same nucleotides bases (97.3% homology), yet small differences have been acknowledged.).

Treatment

Since these bacteria lack a cell wall, they are resistant to antibiotics commonly used for urinary tract infections like penicillins and cephalosporins.

The reason that many individuals get this infection can be damage to the uterus wall lining, causing the bacteria to thrive in a carbon-rich environment.

The types of antibiotics that can be used are quinolones, tetracyclines, and macrolides, since they affect a large part of the mycoplasma family of bacteria where U. urealyticum falls under.

Yet, it is not recommended they are prescribed frequently due to antibiotic resistance.

Other drugs that have β-lactamases are infective to treat infection because of how fast the bacteria's circular genome can mutate (Fan et al. 2023) This helps control the infection where the bacteria grows. Additionally, it is also a great alternative to when a pregnant woman is infected to prevent harm to the fetus, as this antibiotic is transported and acts locally.

Clinical relevance

Ureaplasma urealyticum can cause urethritis and may cause bacterial vaginosis. Infection can occur in extragenital sites. A common symptom associated with these infections is the "fishy" smell that is created due to the production of ammonia by the hydrolysis of urea. Patients should confirm diagnosis with a doctor. The bacterium has high correlations with the Human Papillomavirus (HPV). It has also been linked to infertility in both males and females. In addition, this pathogen may latently infect the chorionic villi tissues of pregnant women, thereby impacting pregnancy outcome. Issues that arise from Ureaplasma urealyticum infections during pregnancy include preterm birth and impacted embryonic development. Some patients have given birth to children subjected to bronchopulmonary dysplasia, Intraventricular hemorrhage, and necrotizing enterocolitis. Patients can evolve resistances to normal antibiotic treatments due to the distinctive physiology of these organisms. In the Western World, approximately 40% of Ureaplasma species are resistant to fluoroquinolones (i.e. ciprofloxacin). Patients who are pregnant have further limitations on the treatment course of a Ureaplasma urealyticum infection, making it far harder to successfully cure.

See also

  • International Organization for Mycoplasmology (IOM)
  • Sexually transmitted infection
  • Vaginal infection
  • Vaginal disease
  • Vaginal health
  • List of bacterial vaginosis microbiota
  • Uterine microbiome
  • Mycoplasma

References

  • Ureaplasma Genome Projects from Genomes OnLine Database
  • Type strain of Ureaplasma urealyticum at BacDive – the Bacterial Diversity Metadatabase